Clinical Trial Update: Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI) [Phase 1]

View source ↗

Summary

A Phase 1 single ascending dose study of SAR439459 in adults with Osteogenesis Imperfecta has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteogenesis Imperfecta

Drugs mentioned

• SAR439459 (sar439459)

Snippet

Sponsor: Sanofi | Conditions: Osteogenesis Imperfecta | Phase 1 | Status: TERMINATED